The Ebola outbreak in DR Congo has surpassed 10,000 cases and nearly 4,900 deaths, and it has spread to Kenya, Uganda and Nigeria. The outbreak involves the Bundibugyo virus, for which there is no approved vaccine or specific treatment.
DR Congo health authorities reported 10,060 Ebola cases and 4,887 deaths since the outbreak was identified in mid-May, according to allAfrica. The sources do not give a date for these figures, so it is unclear how current they are.
The Africa Centres for Disease Control and Prevention described the outbreak as the fastest-growing Ebola outbreak in history, according to allAfrica. The Africa CDC’s statement was included in the sources only as a description; no further details were given.
Kenya has confirmed nine infections, including two deaths, according to allAfrica. Those cases followed a patient who traveled from DR Congo through Uganda to Nairobi.
Separately, the United Nations said Kenya reported its first-ever Ebola case on 6 October, and that eight contacts later tested positive and were moved to the Ebola treatment centre in Nairobi, according to Euronews. The sources do not reconcile this eight-contact figure with the nine confirmed infections reported by allAfrica.
Nigeria confirmed an infection in a Swiss woman, the wife of a Swiss diplomat, who fell ill after visiting Uganda and was evacuated to Switzerland, according to allAfrica. Euronews reported that the European Centre for Disease Prevention and Control (ECDC) sent a team led by its senior expert in epidemic intelligence to Nigeria, which it called the fourth African country to report an Ebola case. No second source was found to confirm the Nigeria case details or the evacuation.
Ebola spreads through direct contact with an infected person’s blood or other bodily fluids. Early symptoms can resemble malaria, which could delay isolation and treatment, according to the sources.
Clinical trials of two antiviral treatment approaches have been underway since July. Two further trials are testing whether the Ervebo vaccine protects against Bundibugyo virus; Ervebo is currently approved only against Ebola virus.
The ECDC’s latest threat assessment says the likelihood of infection among Europeans is very low. It rates the risk as low for people living in or travelling to affected areas of Kenya and Nigeria.
Officials are investigating where the Swiss woman contracted the virus. The Ervebo vaccine trials against Bundibugyo are ongoing, but the sources give no further timeline.
Much of this account relies on allAfrica, and the details of a NPR World report could not be checked beyond a headline and short excerpt. The sources also include no response from DR Congo health authorities or the Africa CDC beyond the reported figures, and a Uganda quarantine order was mentioned only in a headline without details.
Sources
This article was written with AI assistance from the published reporting listed above. It is part of the World Brief daily news podcast.